{"ModuleTitle": "Company Description", "CompanyName": "Alexion Pharmaceuticals, Inc.", "Symbol": "ALXN", "Address": "121 SEAPORT BOULEVARD, BOSTON, Massachusetts, 02210, Switzerland", "Phone": "4752302596", "Industry": "Major Pharmaceuticals", "Sector": "Health Care", "Region": "North America", "CompanyDescription": "Alexion is a global biopharmaceutical company focused on serving patients and\r\nfamilies affected by rare diseases through the discovery, development and\r\ncommercialization of life-changing therapies.\r\nAs the global leader in complement biology and inhibition for more than 20\r\nyears, Alexion has developed and commercializes two approved complement\r\ninhibitors to treat patients with paroxysmal nocturnal hemoglobinuria (PNH) and\r\natypical hemolytic uremic syndrome (aHUS), as well as the first and only\r\napproved complement inhibitor to treat anti-acetylcholine receptor (AChR)\r\nantibody-positive generalized myasthenia gravis (gMG) and neuromyelitis optica\r\nspectrum disorder (NMOSD) in patients who are anti-aquaporin-4 (AQP4) antibody\r\npositive.&nbsp;&nbsp;... <a href=\"http://secfilings.nasdaq.com/edgar_conv_html%2f2020%2f02%2f04%2f0000899866-20-000012.html#FIS_BUSINESS\" target=\"_blank\">More</a> ...&nbsp;&nbsp;\r\n", "KeyExecutives": [{"name": "Aradhana Sarin", "title": "Chief Financial Officer & Executive Vice President"}, {"name": "Brian M. Goff", "title": "Chief Commercial, Global Operations Officer & EVP"}, {"name": "John J. Orloff", "title": "Executive VP, Head-Research & Development"}, {"name": "Ludwig N. Hantson", "title": "Chief Executive Officer & Director"}, {"name": "Paul J. Clancy", "title": "Chief Financial Officer"}], "Number_of_employees": ["2,525"], "Subsidiaries": ["NO INFO"]}